Sid P Kerkar

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Res 70:6725-34. 2010
  2. doi request reprint Cellular constituents of immune escape within the tumor microenvironment
    Sid P Kerkar
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 72:3125-30. 2012
  3. pmc IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 121:4746-57. 2011
  4. pmc The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
    Sid P Kerkar
    Surgery Branch, CCR, NCI, Bethesda, MD, USA
    Trials 10:121. 2009
  5. pmc Th17 cells are long lived and retain a stem cell-like molecular signature
    Pawel Muranski
    National Cancer Institute, Bethesda, MD 20892, USA
    Immunity 35:972-85. 2011
  6. pmc Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice
    Christopher A Klebanoff
    Center for Cancer Research CCR, National Cancer Institute NCI, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:5343-52. 2011
  7. pmc Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment
    Ling Zhang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:751-9. 2011
  8. pmc Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies
    Sid P Kerkar
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 34:343-52. 2011
  9. pmc Collapse of the tumor stroma is triggered by IL-12 induction of Fas
    Sid P Kerkar
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Mol Ther 21:1369-77. 2013
  10. doi request reprint Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice
    Dhanalakshmi Chinnasamy
    National Cancer Institute, Clinical Research Center, Bethesda, MD, USA
    Clin Cancer Res 18:1672-83. 2012

Detail Information

Publications16

  1. pmc Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Res 70:6725-34. 2010
    ..Our findings reveal an approach to genetically modify T cells to reduce the cell number needed, eliminate the need for vaccines or systemic IL-2, and improve immunotherapy efficacy based on adoptive transfer of gene-engineered T cells...
  2. doi request reprint Cellular constituents of immune escape within the tumor microenvironment
    Sid P Kerkar
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 72:3125-30. 2012
    ..A better understanding of the cellular constituents of tumors and the mechanisms involved in immune evasion may help guide the next generation of innovative cancer immunotherapies...
  3. pmc IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 121:4746-57. 2011
    ....
  4. pmc The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
    Sid P Kerkar
    Surgery Branch, CCR, NCI, Bethesda, MD, USA
    Trials 10:121. 2009
    ..Several case reports and small studies have documented evidence of long-term survival in select individuals who undergo CHPP for MGC...
  5. pmc Th17 cells are long lived and retain a stem cell-like molecular signature
    Pawel Muranski
    National Cancer Institute, Bethesda, MD 20892, USA
    Immunity 35:972-85. 2011
    ..Thus, Th17 cells are not always short lived and are a less-differentiated subset capable of superior persistence and functionality...
  6. pmc Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice
    Christopher A Klebanoff
    Center for Cancer Research CCR, National Cancer Institute NCI, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:5343-52. 2011
    ..However, the relative contributions of each these individual components to the magnitude of the antitumor response have yet to be quantified...
  7. pmc Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment
    Ling Zhang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:751-9. 2011
    ..Notably, this targeted and controlled IL-12 treatment was without toxicity. Taken together, our results suggest that using the NFAT.hIL12.PA2 vector might be a promising approach to enhance adoptive cancer immunotherapy...
  8. pmc Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies
    Sid P Kerkar
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 34:343-52. 2011
    ..These results indicate that preclinical murine models of adoptive immunotherapies are more practical using γ-retroviral rather than lentiviral vectors...
  9. pmc Collapse of the tumor stroma is triggered by IL-12 induction of Fas
    Sid P Kerkar
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Mol Ther 21:1369-77. 2013
    ....
  10. doi request reprint Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice
    Dhanalakshmi Chinnasamy
    National Cancer Institute, Clinical Research Center, Bethesda, MD, USA
    Clin Cancer Res 18:1672-83. 2012
    ..We investigated the feasibility of delivering the proinflammatory cytokine interleukin (IL)-12 into tumor using T cells genetically engineered to express a chimeric antigen receptor (CAR) against the VEGF receptor-2 (VEGFR-2)...
  11. pmc Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD, USA
    Blood 117:808-14. 2011
    ..Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy...
  12. pmc Liver resections in metastatic gastric cancer
    Sid P Kerkar
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    HPB (Oxford) 12:589-96. 2010
    ..This review examines the published data on liver resections for MGC and analyses the rationale for potentially aggressive surgical management...
  13. pmc Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma
    Steven Yeh
    National Eye Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Ophthalmology 116:981-989.e1. 2009
    ..To describe the ophthalmic and systemic autoimmune findings after successful adoptive cell transfer of ex vivo expanded, autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) for metastatic melanoma...
  14. ncbi request reprint Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells
    Sid P Kerkar
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Immunology 143:96-108. 2014
    ..Timing and intensity of exposure to IFN-γ can therefore determine the functional capacity of moDC. ..
  15. ncbi request reprint The power and pitfalls of IL-12
    Sid P Kerkar
    National Heart, Lung, and Blood Institute, and National Cancer Institute
    Blood 119:4096-7. 2012
    ..1 These exciting findings significantly extend previous observations made in a murine melanoma model targeting naturally occurring tumor antigens.2,3..